A group of J&J shareholders has filed a complaint against the company, accusing directors of ignoring warnings signs pertaining to J&J's massive product recalls and government probes of manufacturing defects and marketing practices.
The bad news doesn't end for Johnson & Johnson as FDA inspectors continue to find problems at the Pennsylvania plant that was the source of a massive recall of children's medicines earlier this year.
Was Johnson & Johnson aware of problems with its Children's Tylenol months before the recall? The House Oversight Committee has invited an FDA commissioner and Johnson & Johnson chairman to a hearing next week to address this and other questions surrounding the massive recall of children's medicines earlier this year.
Still in hot water over its "phantom recall" of a Motrin product, Johnson & Johnson looks to expand its share of the vaccine market with purchase of Dutch pharma company Crucell.
In a warning letter to J&J's DePuy Orthopaedics, the FDA says it is illegally marketing its TruMatch CT scanner and Corail Hip System. This is the latest in a series of problems at J&J, which include a big children's Tylenol recall.
A House panel will hold a second hearing, postponed until sometime after June 30, to examine the recall of more than 135 million bottles of infant and children's medicines produced by J&J's McNeil Consumer Healthcare unit. This time the boss is expected to show.
It's been about a month since Johnson & Johnson issued the largest-ever recall of children's medicine, but the fallout may be just beginning. Representatives from both J&J and the FDA are scheduled to testify at a May 27 congressional hearing as lawmakers remain concerned about how the recall was handled.
